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Abstract Purpose: To assess the
severity of intensive care unit (ICU)-
acquired pneumonia (ICUAP)
according to the bacteria involved,
classified into seven groups: third-
generation cephalosporin-resistant
non-fermenting Gram-negative bacilli









Methods: Over a 4-year period,
sequential organ failure assessment
(SOFA) score was prospectively
measured daily in 453 adult patients
with ICUAP. ICUAP severity was
evaluated by the severity of sepsis
and by the occurrence of new organ
dysfunctions or failures (OD/F) dur-
ing ICUAP. Results: Septic shock
occurred in 21% of all cases of
ICUAP. The occurrence of new OD/F
during ICUAP was similar regardless
of the identified microorganism.
These new OD/F represented less
than 11% of SOFAmax, defined as
the sum of all OD/F occurring at any
time during the ICU stay. There was a
significant association between SOF-
ApreICUAP, defined as the sum of all
the OD/F occurring before ICUAP,
and ICUAP severity. In the multi-
variate analysis, the type of bacteria
was not a risk factor (RF) for occur-
rence of septic shock and mortality.
Age and SOFApreICUAP were RF
for the sepsis severity. The ICUAP
severity was an RF for ICU mortality.
Conclusions: ICUAP was responsi-
ble for a minor proportion of OD/F
occurring during the ICU stay.
Severity of ICUAP was related to
clinical status prior to ICUAP, but not
to the type of bacteria. ICU mortality
depended on the severity of ICUAP.




ICU-acquired pneumonia (ICUAP) and especially venti-
lator-associated pneumonia (VAP) are the most common
infections in ICU patients and are attributed the highest
infection-related mortality [1]. Several factors linked to
mortality have been identified: the underlying diseases
[2, 3], the severity of the infectious episode (septic shock
being an independent risk factor) [3], the type of bacteria
(non-fermenting being an independent risk factor) [4, 5],
and the appropriateness of antibiotic therapy [2, 6]. We
recently reported global data about organ dysfunction or
failure (OD/F), as assessed by the sequential organ failure
assessment (SOFA) score, occurring during ICU-acquired
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infections [7]. The latter contributed only to a minor
proportion of OD/F [7]. However, the type of microor-
ganisms involved in the infectious process was not taken
into account. The aim of the present study was therefore
to extend the analysis of ICUAP by investigating the role
played by commonly encountered pathogens, classified
according to their difficulty to be treated, i.e., their type
and antibiotic resistance.
Materials and methods
This single-center study was prospectively conducted
from 1 January 2004 to 31 December 2007 in a 26-bed
ICU at Liege University Hospital, Belgium.
Patients
All consecutive patients, older than 18 years of age, who
stayed for more than 48 h in the ICU were included in the
study. Age, gender, simplified acute physiology score
(SAPS) II obtained from the first 24 h in the ICU [8], and
the following underlying diseases were recorded: coro-
nary artery disease, chronic obstructive pulmonary
disease, chronic heart failure, cirrhosis, chronic renal
failure requiring dialysis, cancer, and hematological
malignancies. The severity of the underlying disease was
assessed using McCabe and Jackson’s classification [9].
The type of admission was classified into traumatic,
unscheduled surgery, scheduled surgery, and medical. For
patients admitted to the ICU more than once during the
same hospital stay, only the first ICU period was
recorded.
Infection control policy included continuous surveil-
lance of nosocomial infections, isolation procedures, and
routine screening for colonization. Antibiotic treatment
was based on local antibiotic guidelines with treatment
duration of 8 to 10 days even for non-fermenting organ-
isms [10]. The treatment was considered appropriate
when at least one drug from the first empiric antibiotic
treatment course was active against the responsible
pathogen(s) within 24 h of clinical diagnosis. During the
study period, no selective digestive decontamination was
performed and subglottic suction devices were not used.
VAP prevention included 30 head positioning and mouth
disinfection with 0.2% chlorhexidine once per nursing
shift. A closed endotracheal suction system, allowing
suctioning as frequently as needed, was used for each
intubated patient who had to be ventilated for more than
24 h.
The hospital ethics committee approved the study
design and the requirement of informed consent was
waived because of its epidemiological and noninterven-
tional design.
Definitions
ICUAP was defined as a new and persistent infiltrate on
chest radiography occurring more than 48 h after ICU
admission and associated with at least two of the fol-
lowing: fever of above 38.3C, leukocyte count of greater
than 11,000/mm3, and purulent aspirate. In addition, at
least one pathogen had to be identified in significant
number by semiquantitative culture of tracheal aspirate.
ICUAP was classified according to microorganisms into
one of the following seven groups: group 1, third-gener-
ation cephalosporin-resistant non-fermenting Gram-
negative bacilli; group 2, third-generation cephalosporin-
sensitive non-fermenting Gram-negative bacilli; group 3,
methicillin-resistant Staphylococcus aureus (MRSA);
group 4, methicillin-sensitive Staphylococcus aureus
(MSSA); group 5, extended-spectrum beta-lactamase
(ESBL)-producing Enterobacteriaceae; group 6, Entero-
bacteriaceae not producing ESBL; group 7, Haemophilus
influenzae and Streptococcus pneumoniae. If two or more
pathogens were found, the corresponding ICUAP episode
was classified according to the most difficult to treat
pathogen.
Severity of illness
The severity of ICUAP was assessed by two methods:
first, using the criteria for sepsis and organ failure as
defined by the American College of Chest Physicians/
Society of Critical Care Medicine (ACCP/SCCM) con-
ference [11]; secondly, using the SOFA score and several
derived indices [7, 12, 13]. According to the ACCP/
SCCM conference recommendation [11] only new or
worsened OD/F were considered as related to infection
and used to determine sepsis severity. For instance, a
patient with cardiogenic shock due to myocardial infarc-
tion who developed a VAP would have been classified as
simple sepsis if the degree of OD/F remained unchanged
in terms of specific clinical parameters and need for organ
support. In the absence of other obvious explanations,
OD/F occurring within 24 h preceding the clinical diag-
nosis of an infection were attributed to this infection and
taken into account for sepsis severity assessment. Patients
suffering from sepsis or simple infection were grouped
together as proposed by Alberti et al. and classified as
having ‘‘simple sepsis’’ [14].
The SOFA score was calculated daily during the ICU
stay following its original description [12]. For the car-
diovascular system, a SOFA score of 0 was recorded if
vasopressors were used to optimize cerebral perfusion
(e.g., in neurotrauma patients). For the central nervous
system, the Glasgow coma scale (GCS) was assessed
without sedation. In cases of mandatory sedation, the
GCS was considered equal to that observed before seda-
tion, usually 15/15. We calculated the SOFAmax, defined
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by Moreno et al. [13] as the sum of the worst scores for
each organ component observed at any time during the
ICU stay. The SOFAmax was then split into different
components derived from daily SOFA calculation (Fig 1):
SOFA for the first ICU day, deltapreICUAP calculated as
the sum of new OD/F observed before the occurrence of
ICUAP, deltaperICUAP corresponding to new OD/F
related to the episode of ICUAP, and deltapostICUAP
corresponding to new episodes of infection after ICUAP.
Severity of ICUAP was, hence, evaluated by the corre-
sponding deltaperICUAP. Furthermore, severity was also
assessed by calculating SOFAperICUAP which was the
sum of the worst scores observed during the usual
8–10 days’ treatment of ICUAP and comparing it to a
SOFApreICUAP, which, in the same way, was the sum of
the worst scores observed before the occurrence of ICU-
AP (Fig 1). SOFApreICUAP is therefore the sum of
SOFA for the first day plus deltapreICUAP, and SOFA-
max is the sum of SOFA for the first day plus
deltapreICUAP, deltaperICUAP, and deltapostICUAP.
Bacterial identification, susceptibility testing,
and detection of ESBL
Gram-negative bacilli and staphylococcal isolates had
been identified and tested for susceptibility by the Vitek 2
system using GN, GP, and AST cards (bio-Merieux,
France). The presence of ESBL in Enterobacteriaceae
was screened by the double disk synergy test with three
different cephalosporin substrates (cefotaxime, ceftazi-
dime, and cefepime) and clavulanate or by ESBL E tests
[15]. Other types of isolates such as Streptococcus
pneumoniae were identified by using the API System,
conventional tests, and agglutination tests. For these iso-
lates, antimicrobial susceptibility testing was performed
by disc diffusion according to CLSI recommendations
and minimum inhibitory concentrations (MICs) were
obtained by the E test method (ABBiodisc, Sweden). The
E test was performed in accordance with the manufac-
turer’s instructions.
Statistical analysis
For continuous variables, results are given as mean ±
standard deviation or as median with interquartile range
(IQR) when normality was not verified. Categorical
variables are presented as number and percentages.
Group characteristics were compared using the like-
lihood chi-square test or Kruskal–Wallis test as
appropriate. We compared SOFA scores between groups
using the Kruskal–Wallis test and those within groups
using the Wilcoxon matched-pairs signed rank test.
Statistical tests were performed using SAS software
(version 9.1.3 Service Pack 4, SAS Institute Inc., Cary,
NC, USA). Univariate and multivariate logistic regression
models were used to assess associations linking estab-
lished risk factors with the severity of sepsis and ICU
mortality. Because severity of sepsis comprises three
modalities (simple sepsis, severe sepsis, and septic shock)
the logistic analysis followed an ordinal regression.
Results were considered significant when p \ 0.05.
Results
Over the 4-year period, 2,422 patients older than 18 years
of age stayed in the ICU for more than 48 h and
accounted for 29,611 ICU days. The median length of
ICU stay was 7 days (IQR 4–15). Six hundred and eighty
patients (28.6%) acquired 1,088 infections during their
ICU stay. Among them, 453 developed 595 ICUAP and
205 other infections. Of these 453 patients only 18 were
not ventilated at all, the 435 others were ventilated for a
median of 18 days (IQR 9–28). Within the 453 patients
who contracted ICUAP, 348 (76.8%) had one single
episode of ICUAP, 77 (17%) had 2 episodes, 21 (4.6%)
had 3 episodes, 5 (1.1%) had 4 episodes, and 2 (0.4%) had
5 episodes. Overall, 86/595 (14.5%) of ICUAP were
responsible for a concomitant bacteremia, and 92/595
(15.5%) were diagnosed together with another infection.
SOFA-D1 








(sum of all OD/F) 
SOFA perICUAP 








Fig. 1 Calculation of SOFAmax and others derived scores. The
ICU stay is divided into three time intervals according to the
occurrence of intensive care unit-acquired pneumonia (ICUAP) and
possibly other ICU-acquired infection (IAI) after ICUAP. SOFA-
D1 is the sequential organ failure assessment score of the first day.
The deltapreICUAP, deltaperICUAP, and deltapostICUAP are the
new organ dysfunctions or failures (OD/F) occurring during the
corresponding time interval. Therefore SOFAmax is the sum of
SOFA-D1 and the three delta values. SOFA preICUAP and SOFA
perICUAP are the sum of all OD/F existing during the correspond-
ing time interval. SOFA sequential organ failure assessment
1130
Severe sepsis occurred in 99/595 (17%) of ICUAP and
septic shock in 128/595 (21%). Treatment was appropri-
ate in 481/595 (80.8%) of the cases.
Microorganisms belonging to one single group were
found in 434 of 595 ICUAP (72.9%), to two groups in 151
ICUAP (25.4%), and to three groups in 10 ICUAP (1.7%).
Enterobacteriaceae were encountered in 357 ICUAP
(60%), non-fermenting Gram-negative bacilli in 204 I-
CUAP (34.3%), Staphylococcus aureus in 122 ICUAP
(20.5%), and other bacteria in 66 (11.1%). Table 1 shows
the classification of ICUAP according to the seven dif-
ferent groups of microorganisms, distinguishing the first
episode from the subsequent ones. It also shows the
severity of ICUAP expressed either by the degree of
sepsis or by the SOFAperICUAP. The SOFApreICUAP
appeared higher than SOFAperICUAP whichever the
group (p \ 0.0001). This indicates that there were more
OD/F during the period preceding the ICUAP than during
the ICUAP itself. However, the severity of sepsis was not
homogeneously distributed amongst the microorganisms
groups: indeed, septic shock occurred more frequently in
ICUAP caused by third-generation cephalosporin-resis-
tant non-fermenting Gram-negative bacilli (group 1)
(p \ 0.001). Interestingly SOFAperICUAP but also
SOFApreICUAP followed the same distribution, being
the lowest in group 7 (7.6 ± 3.7) and the highest in group
1 (12.8 ± 4.8) (p \ 0.0001) (Table 2). Accordingly,
there was a significant positive correlation between
SOFApreICUAP and the rate of severe sepsis or septic
shock within the groups (Fig. 2) (p = 0.0036, r2 = 0.84).
Figure 3 shows the partition of SOFAmax according
to the time interval during which OD/F occurred, taking
only the first episode of ICUAP into account. The SOFA
from 1st day in the ICU accounted for 61.4 ± 22.9% of
the SOFAmax, deltapreICUAP accounted for 25.7 ±
20.8% of SOFAmax, and deltaperICUAP represented
10.2 ± 14.6% of SOFAmax. These proportions were not
different between groups.
Table 2 shows that the patients’ characteristics clas-
sified according to the microorganisms causing their first
ICUAP episode were very different in terms of age, past
medical history, and lengths of ICU and hospital stay.
This was also shown for the severity of acute illness as
assessed by the SOFAmax. As expected, the rate of
treatment appropriateness was also different. Only the
SAPS II score was not statistically significantly different
between microorganisms groups.
The multivariate ordinal analysis identified only three
statistically significant factors for occurrence of severe
sepsis or septic shock: age, presence of a rapidly fatal
disease, and SOFApreICUAP. The type of microorganism
was not considered as significant (Table 3). Considering
ICU mortality (Table 4), the multivariate analysis iden-
tified the following as significant risk factors: age, the
presence of ultimately or rapidly fatal disease, and the
severity of ICUAP. Neither the type of bacteria nor the
appropriateness of treatment was retained in the analysis;
this was also true for hospital mortality (data not shown).
On the other hand, scheduled surgery appeared to be a
protective clinical entity.
Table 1 Distribution and characteristics of ICU acquired pneumonia








Number 31 92 27 68 36 162 37
SOFApreICUAP 12.1 ± 5 11.3 ± 4.4 9.9 ± 4.2 8.3 ± 3.2 12.8 ± 4.8 10.4 ± 4.1 7.6 ± 3.7 \0.0001
SOFAperICUAP 11.3 ± 5.8 9.6 ± 5.3 7.9 ± 4.8 6.7 ± 3.4 10.1 ± 5.6 8.0 ± 4.6 6.2 ± 3.5 \0.0001
DeltaperICUAP 1 (0–3.5) 0 (0–3) 0 (0–2.5) 0 (0–1) 0 (0–2) 0 (0–2) 0 (0–1) 0.3823
Simple sepsis 12 (38.7%) 54 (58.7%) 17 (63%) 51 (75%) 18 (50%) 97 (59.9%) 28 (75.7%)
Severe sepsis 6 (19.4%) 14 (15.2%) 4 (14.8%) 10 (14.7%) 10 (27.8%) 30 (18.5%) 3 (8.1%) 0.0279
Shock 13 (41.9%) 24 (26.1%) 6 (22.2%) 7 (10.3%) 8 (22.2%) 35 (21.6%) 6 (16.2%)
Appropriateness 21 (67.7%) 72 (78.3%) 22 (81.5%) 60 (88.2%) 24 (66.7%) 141 (87%) 33 (89.2%) 0.0094
Subsequent episodes
Number 40 41 5 5 34 16 1
Simple sepsis 21 (52.5%) 29 (70.7%) 5 (100%) 2 (40%) 22 (64.7%) 11 (68.8%) 1 (100%)
Severe sepsis 6 (15%) 7 (17.1%) 0 1 (20%) 5 (14.7%) 3 (18.8%) 0 0.4569
Shock 13 (32.5%) 5 (12.2%) 0 2 (40%) 7 (20.6%) 2 (12.5%) 0
ICUAP intensive care unit-acquired pneumonia, C3RNF third-
generation cephalosporin-resistant non-fermenting Gram-negative
bacilli, C3SNF third-generation cephalosporin-sensitive non-fer-
menting Gram-negative bacilli, ESBL prod Enterob extended-
spectrum beta-lactamase-producing Enterobacteriaceae, Enterobact
not prod ESBL Enterobacteriaceae not producing extended-spectrum
beta-lactamase, MRSA methicillin-resistant Staphylococcus aureus,
MSSA methicillin-sensitive Staphylococcus aureus, Hae inf, S pneu
Haemophilus influenzae and Streptococcus pneumoniae, SOFA
sequential organ failure assessment, SOFApreICUAP sum of all the
organ dysfunctions/failures occurring before ICUAP, SOF-




Determining the contribution of ICUAP to patients’
severity of illness is a major challenge. In order to relate
new OD/F occurring during the ICU stay to clinical
events, we measured the SOFA score daily and calculated
some derived scores. Whereas SOFAmax measured organ
failures for the whole ICU stay, SOFAperICUAP pro-
vided information on all the OD/F observed during the
ICUAP episode only and deltaperICUAP was used to
estimate the new OD/F that occurred during ICUAP.
These partial SOFA scores were obtained by summing OD/F
that occurred during a particular time interval. This is, in our
view, a better method to characterize the true severity of
illness as compared to the use of mean daily SOFA score.
Indeed, the latter approach, by averaging, leads to a loss of
relevant information. Interestingly, our approach is similar to
SOFAmax calculation which is the best mortality predictor,
derived from SOFA score, to date [13].
In order to focus the analysis on the type of micro-
organism(s), we chose to classify them simply, ranging
from the most resistant pathogenic microorganisms to the
lesser ones, i.e., non-fermenting Gram-negative bacilli
first, Staphylococcus aureus second, Enterobacteriaceae
third, and other microbes in fourth place. Then, we sep-
arated within the first three groups those presenting
Table 2 Characteristics of patients
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 p
C3RNF C3SNF MRSA StaAur ESBL Enterobacteriaceae Other
Number 31 92 27 68 36 162 37
Age 60 (41–78) 68 (50–78) 66 (55–76) 63 (48–76) 65 (55–76) 63 (50–74) 53 (45–66) 0.0065
Female sex 6 (19.4%) 35 (38.0%) 7 (25.9%) 25 (36.8%) 8 (22.2%) 40 (24.7%) 5 (13.5%) 0.0322
Medical 14 (45.2%) 38 (41.3%) 9 (33.3%) 18 (26.5%) 15 (41.7%) 39 (24.1%) 5 (13.5%) \0.0001
Scheduled surgery 7 (22.6%) 18 (19.6%) 10 (37.0%) 6 (8.8%) 6 (16.7%) 27 (16.7%) 4 (10.8%)
Emergency surgery 9 (29.0%) 22 (23.9%) 4 (14.8%) 24 (35.3%) 12 (33.3%) 55 (34.0%) 10 (27.0%)
Trauma 1 (3.2%) 14 (15.2%) 4 (14.8%) 20 (29.4%) 3 (8.3%) 41 (25.3%) 18 (48.6%)
Ultimately fatal 12 (38.7%) 22 (23.9%) 8 (29.6%) 9 (13.2%) 15 (41.7%) 37 (22.8%) 3 (8.1%)
Rapidly fatal 8 (25.8%) 9 (9.8%) 4 (14.8%) 1 (1.5%) 4 (11.1%) 13 (8.0%) 0 (0%) \0.0001
Previous hospitalization 23 (74.2%) 33 (35.9%) 9 (33.3%) 15 (22.1%) 17 (47.2%) 41 (25.3%) 4 (10.8%) \0.0001
Hospital delay 4 (0–12) 2 (0–9) 0 (0–2) 0 (0–2) 2 (1–11) 1 (0–3) 1 (0–1) 0.0071
ICU delay before
ICUAP
10 (7–19) 9 (6–14) 9 (6–12) 5 (4–7) 15 (9–23) 9 (5–13) 6 (4–7) \0.0001
ICU LOS 33 (20–41) 23 (17–35) 17 (10–29) 17 (10–29) 32 (21–44) 26 (15–39) 18 (13–26) \0.0001
Hospital LOS 42 (33–70) 44 (31–71) 32 (17–52) 32 (17–52) 57 (39–72) 47 (30–64) 32 (24–49)
Infection on admission 23 (74.2%) 39 (42.4%) 7 (25.9%) 4 (5.9%) 26 (72.2%) 62 (38.3%) 2 (5.4%) \0.0001
SAPS II 48.4 ± 12.3 45.4 ± 14.9 40.8 ± 14.2 44.2 ± 15.3 45.5 ± 13.4 4308 ± 12.4 39.5 ± 13.6 0.0738
ICU mortality 14 (45.2%) 34 (37.0%) 7 (25.9%) 19 (27.9%) 16 (44.4%) 40 (24.7%) 3 (8.1%) 0.0025
Hospital mortality 16 (51.6%) 51 (55.4%) 11 (40.7%) 22 (32.4%) 20 (55.6%) 55 (34.0%) 4 (10.8%) \0.0001










































Fig. 2 Relationship between the percentage of severe sepsis and
septic shock occurrence during ICU acquired pneumonia classified
by their infective microorganisms and the corresponding SOF-
ApreICUAP. ESBL? Enterobact extended-spectrum beta-
lactamase-producing Enterobacteriaceae, ESBL- Enterobact
Enterobacteriaceae not producing extended spectrum beta-lacta-
mase, other abbreviations are defined in Table 1
0 2 4 6 8 10 12 14 16
Hae inf, S pneu
MSSA
MRSA








Fig. 3 Partition of the SOFAmax into its constitutive parts.
DeltapreICUAP, deltaperICUAP, deltapostICUAP sum of the
new organ failures or dysfunctions occuring prior, during or after
ICUAP, respectively; other abbreviations are defined in Table 1
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antibiotic resistance thus leading to seven different
mutually exclusive ICUAP entities. It should be noted
that this is derived from common clinical practice on
initiation of empiric antibiotic treatment. As shown in
Table 2, we found the expected differences between
groups in terms of age, past medical history, underlying
diseases, delay between hospitalization and ICU admis-
sion, delay between ICU admission and occurrence of
Table 3 Risk factors for the occurrence of severe sepsis or septic shock: ordinal logistic regression
Effect Point estimate Confidence limits p value
Age 1.017 1.004 1.031 0.0126
Sex (M vs. F) 0.94 0.604 1.463 0.7834
Hospital delay 0.996 0.982 1.01 0.5376
Previous hospital 1.031 0.665 1.599 0.8923
Ultimately fat vs. non fatal 1.544 0.964 2.473 0.0705
Rapidly fatal versus non fatal 2.042 1.001 4.165 0.0496
SAPS II score 0.989 0.972 1.006 0.197
Type of patients
Scheduled surgery versus medical 1.265 0.696 2.3 0.4411
Emergency surgery versus medical 0.653 0.393 1.085 0.1002
Trauma versus medical 0.609 0.316 1.175 0.1391
Infection on admission 1.247 0.775 2.007 0.3626
SOFApreICUAP 1.06 1.004 1.118 0.0344
Type of microorganisms
MSSA versus other 0.723 0.28 1.868 0.5032
MRSA versus other 0.845 0.278 2.57 0.7664
Enterob ESBL- versus other 1.207 0.52 2.801 0.6619
Enterob ESBL? versus other 1.263 0.426 3.745 0.6738
C3SNF versus other 1.117 0.451 2.767 0.8115
C3RNF versus other 1.05 0.63 1.748 0.8518
Appropriateness 1.05 0.63 1.748 0.8518
ICUAP delay 0.979 0.953 1.005 0.1138
Enterob ESBL- Enterobacteriaceae not producing extended-spectrum beta-lactamase, Enterob ESBL? Enterobacteriaceae producing
extended-spectrum beta-lactamase, other abbreviations are defined in Table 1
Table 4 Risk factors for ICU mortality: multivariate logistic regression
Effect Point estimate 95% confidence limits p value
Age 1.033 1.015 1.052 0.0004
Sex (M vs. F) 0.977 0.565 1.69 0.9344
Hospital delay 1.009 0.993 1.025 0.2751
Previous hospital 1.234 0.719 2.117 0.4456
Ultimately fat versus non fatal 2.359 1.335 4.168 0.0031
Rapidly fatal versus non fatal 8.796 3.538 21.865 \0.0001
SAPS II score 0.996 0.975 1.017 0.7111
Type of patients
Scheduled surgery versus medical 0.423 0.195 0.918 0.0296
Emergency surgery versus medical 0.928 0.507 1.699 0.8088
Trauma versus medical 0.632 0.271 1.475 0.2891
Infection on admission 0.771 0.422 1.408 0.3979
SOFApreICUAP 1.051 0.982 1.124 0.1498
Severity of ICUAP
Severe sepsis versus simple sepsis 2.629 1.378 5.015 0.0033
Septic shock versus simple sepsis 5.392 3.011 9.655 \0.0001
Type of microorganisms
MSSA versus other 3.426 0.851 13.797 0.0831
MRSA versus other 1.503 0.3 7.538 0.6201
Enterob ESBL- versus other 1.54 0.401 5.921 0.5294
Enterob ESBL? versus other 2.836 0.584 13.767 0.1959
C3SNF versus other 2.386 0.593 9.602 0.2208
C3RNF versus other 2.008 0.401 10.048 0.3961
Appropriateness 1.048 0.557 1.97 0.8854
ICUAP delay 0.995 0.961 1.03 0.7737
Abbreviations are defined in Tables 1 and 3
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ICUAP, corresponding to what is already known in the
literature [16, 17].
The originality of the present study lies in the description
of OD/F over the entire ICU course using a score developed
for that purpose [12]. Thus, it differs from recent studies on
severity of sepsis or VAP that measured SOFA score [18], a
new score called VAP-PIRO [19], or the LOD score [20]
from the day of infection. In our study, we found that delta
SOFA related to ICUAP explained only 10.3% of the
SOFAmax which was by far lower than the contribution of
SOFApreICUAP (the sum of SOFA-D1 and del-
tapreICUAP), which accounted for 87.5% of SOFAmax
(Fig. 3). This corresponds to our previous results [7]. This
surely puts the relationship between VAP and its attributable
mortality into a new perspective and may also explain why
prevention measures of VAP did not have a favorable impact
on mortality in many studies, as recently discussed by
Klompas [21].
Twenty-one percent of ICUAP were severe enough to
cause septic shock. Table 1 suggests that severity may
depend on the type of bacteria involved in the infectious
process because septic shock seemed to occur more often
when third-generation cephalosporin-resistant non-fer-
menting Gram-negative bacilli were encountered.
Interestingly, once again, severity of ICUAP, assessed by the
occurrence of septic shock or severe sepsis, seemed to be
mainly related to patients’ clinical status before ICUAP, as
shown by Fig. 2. The determination coefficient r2 shows that
84% of the variability in the incidence of shock or severe
sepsis between the different groups of microorganisms is
actually explained by the variability of the SOFApreICUAP.
We have to insist here on the fact that this is not due to a
linkage of measures because OD/F already existing before
ICUAP could not be used to define the severity of ICUAP.
The multivariate ordinal logistic analysis corroborated this
observation by demonstrating that age and SOFApreICUAP
were risk factors for the occurrence of severe sepsis and
septic shock. One will note that such an approach mainly
attributes the severity of sepsis to preexisting OD/F. There-
fore, our assumption is not in concordance with the currently
accepted theory of sepsis in which an exacerbated host
response to infection is solely incriminated [22, 23].
The multivariate analysis did not show infection by
any particular group of microorganisms to be a risk factor
for ICU mortality. Although many studies found that
antibiotic treatment appropriateness is an independent risk
factor for mortality [2, 6, 24], the present study did not
confirm this finding, like others [25].
Nevertheless, the present study has weaknesses: its
single-center design may be criticized. However, our data
and patients’ characteristics were not different from other
large recent epidemiological studies [26, 27]. Another
flaw concerns the lack of systematic quantitative cultures
as part of the ICUAP definition. However this point is still
controversial in the literature [28, 29]. A recent pro-
spective study could not prove the usefulness of
quantitative cultures [30]. Also, the ICUAP rates we
observed (20/1,000 days or 35/1,000 ventilator days) may
appear quite high, but even higher rates are not uncom-
mon in tertiary referral centers [31]. As a matter of fact,
the exact same rate was recently corroborated and pub-
lished in the control group of a randomized controlled
trial on VAP and subglottic suction [32]. Magret et al.
[33] very recently reported the incidence of VAP in 2,436
patients ventilated for more than 48 h in 27 ICU from
nine European countries: they found 465 patients who
developed VAP, thus close to the present figures.
Conclusion
The severity of ICUAP did not seem to depend on the
types of bacteria involved. ICUAP contributed to a minor
proportion of OD/F occurring during the ICU stay but was
responsible for severe sepsis or septic shock in 38% of the
cases. Patients’ clinical condition prior to ICUAP was an
important factor for infection severity. The high number
of OD/F preceding ICUAP and the relationship between
OD/F and the severity of ICUAP put the relationship
between ICUAP and its attributable mortality into a new
perspective. The SOFA score provides us with a good tool
to assess the impact of events occurring during the ICU
stay, especially in the setting of infection.
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